Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL

Blood Adv (2024) 8 (12): 3226–3236.

https://doi.org/10.1182/bloodadvances.2023012430

Published: 2024

Includes: Supplemental data

Journal Articles

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia

Blood Adv (2024) 8 (4): 909–915.

https://doi.org/10.1182/bloodadvances.2023012231

Published: 2024

Includes: Supplemental data

Journal Articles

Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead

Oren Pasvolsky, Partow Kebriaei, Bijal D. Shah, Elias Jabbour, Nitin Jain

Blood Adv (2023) 7 (14): 3350–3360.

https://doi.org/10.1182/bloodadvances.2022009462

Published: 2023

Journal Articles

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Blood Adv (2023) 7 (13): 3284–3296.

https://doi.org/10.1182/bloodadvances.2022009391

Published: 2023

Includes: Supplemental data

Journal Articles

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Adv (2023) 7 (6): 933–942.

https://doi.org/10.1182/bloodadvances.2022008316

Published: 2023

Includes: Supplemental data

Journal Articles

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

Hussein A. Abbas, Hanxiao Sun, Sherry Pierce, Rashmi Kanagal-Shamanna, Ziyi Li, Musa Yilmaz, Gautam Borthakur, Adam J. DiPippo, Elias Jabbour, Marina Konopleva, Nicholas J. Short, Courtney DiNardo, Naval Daver, Farhad Ravandi, Tapan M. Kadia

Blood Adv (2023) 7 (5): 828–831.

https://doi.org/10.1182/bloodadvances.2022007172

Published: 2023

Includes: Supplemental data

Journal Articles

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Blood Adv (2022) 6 (13): 4006–4014.

https://doi.org/10.1182/bloodadvances.2022007378

Published: 2022

Includes: Supplemental data

Journal Articles

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

Naveen Pemmaraju, Nathaniel R. Wilson, Guillermo Garcia-Manero, Koji Sasaki, Joseph D. Khoury, Nitin Jain, Gautam Borthakur, Farhad Ravandi, Naval Daver, Tapan Kadia, Courtney DiNardo, Elias Jabbour, Sherry Pierce, Muzaffar Qazilbash, Marina Konopleva, Hagop Kantarjian

Blood Adv (2022) 6 (10): 3027–3035.

https://doi.org/10.1182/bloodadvances.2021006645

Published: 2022

Includes: Supplemental data

Journal Articles

Outcomes of acute lymphoblastic leukemia with KMT2A ( MLL ) rearrangement: the MD Anderson experience

Guillaume Richard-Carpentier, Hagop M. Kantarjian, Guilin Tang, C. Cameron Yin, Joseph D. Khoury, Ghayas C. Issa, Fadi Haddad, Nitin Jain, Farhad Ravandi, Nicholas J. Short, Courtney D. DiNardo, Koichi Takahashi, Marina Y. Konopleva, Naval G. Daver, Tapan Kadia, Guillermo Garcia-Manero, Rebecca Garris, Susan O’Brien, Elias Jabbour

Blood Adv (2021) 5 (23): 5415–5419.

https://doi.org/10.1182/bloodadvances.2021004580

Published: 2021

Journal Articles

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy

Hussein A. Abbas, Zoe Alaniz, Sean Mackay, Matthew Cyr, Jing Zhou, Ghayas C. Issa, Mansour Alfayez, Jairo Matthews, Steven M. Kornblau, Elias Jabbour, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Naval Daver

Blood Adv (2021) 5 (22): 4569–4574.

https://doi.org/10.1182/bloodadvances.2021004583

Published: 2021

Includes: Supplemental data

Journal Articles

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse

Bachar Samra, Joseph D. Khoury, Kiyomi Morita, Farhad Ravandi, Guillaume Richard-Carpentier, Nicholas J. Short, Siba El Hussein, Philip Thompson, Nitin Jain, Hagop Kantarjian, Elias Jabbour

Blood Adv (2021) 5 (20): 3913–3918.

https://doi.org/10.1182/bloodadvances.2021004427

Published: 2021

Includes: Supplemental data

Journal Articles

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Blood Adv (2021) 5 (16): 3163–3173.

https://doi.org/10.1182/bloodadvances.2020003829

Published: 2021

Journal Articles

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Blood Adv (2021) 5 (8): 2173–2183.

https://doi.org/10.1182/bloodadvances.2020004173

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML

Nicholas J. Short, Hind Rafei, Naval Daver, Hyunsoo Hwang, Jing Ning, Jeffrey L. Jorgensen, Tapan M. Kadia, Courtney D. DiNardo, Sa A. Wang, Elias Jabbour, Uday Popat, Betul Oran, Jorge Cortes, Marina Konopleva, Musa Yilmaz, Ghayas C. Issa, Hagop Kantarjian, Farhad Ravandi

Blood Adv (2020) 4 (24): 6117–6126.

https://doi.org/10.1182/bloodadvances.2020002811

Published: 2020

Includes: Supplemental data

Journal Articles

Outcome of patients with IDH1/2- mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Helen T. Chifotides, Lucia Masarova, Mansour Alfayez, Naval Daver, Yesid Alvarado, Elias Jabbour, Marina Konopleva, Hagop M. Kantarjian, Keyur P. Patel, Courtney D. DiNardo, Srdan Verstovsek

Blood Adv (2020) 4 (21): 5336–5342.

https://doi.org/10.1182/bloodadvances.2020001528

Published: 2020

Journal Articles

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia

Blood Adv (2020) 4 (8): 1670–1677.

https://doi.org/10.1182/bloodadvances.2019001156

Published: 2020

Includes: Supplemental data

Journal Articles

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Blood Adv (2020) 4 (7): 1311–1320.

https://doi.org/10.1182/bloodadvances.2019001267

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Blood Adv (2020) 4 (3): 482–495.

https://doi.org/10.1182/bloodadvances.2019001101

Published: 2020

Includes: Supplemental data

Journal Articles

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Blood Adv (2019) 3 (6): 922–933.

https://doi.org/10.1182/bloodadvances.2018026989

Published: 2019

Includes: Supplemental data

Journal Articles

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Preetesh Jain, Hagop Kantarjian, Prajwal C. Boddu, Graciela M. Nogueras-González, Srdan Verstovsek, Guillermo Garcia-Manero, Gautam Borthakur, Koji Sasaki, Tapan M. Kadia, Princy Sam, Hycienth Ahaneku, Susan O’Brien, Zeev Estrov, Farhad Ravandi, Elias Jabbour, Jorge E. Cortes

Blood Adv (2019) 3 (6): 851–861.

https://doi.org/10.1182/bloodadvances.2018025874

Published: 2019

Includes: Supplemental data

NARROW

Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia

Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

Outcomes of acute lymphoblastic leukemia with KMT2A ( MLL ) rearrangement: the MD Anderson experience

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML

Outcome of patients with IDH1/2- mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only